Our results with BCR-ABL/TEL-ABL negative ALL cells demonstrate for the first time that the antiproliferative and proapoptotic effects of the dual inhibitors NVP-BGT226 and NVP-BEZ235 are comparable to those in ABL-translocated ALL. Here, ETV6 is linked to acute lymphoblastic leukemia.